Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Survodutide improves insulin sensitivity in type 2 diabetes
Last updated September 12, 2026
Key finding
The mean (SD) absolute change in HOMA-β from baseline at week 17 for survodutide 1.8 mg given twice weekly (BIW) versus placebo was 47.00 (42.50) versus 5.44 (35.32).
The study evaluated the effects of Survodutide on beta-cell function and insulin sensitivity in adults with Type 2 Diabetes, finding significant improvements compared to placebo.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
The study evaluated the effects of Survodutide on beta-cell function and insulin sensitivity in adults with Type 2 Diabetes, finding significant improvements compared to placebo.
Clinical relevance
Improving beta-cell function and insulin sensitivity is crucial for managing Type 2 Diabetes, as these factors are directly linked to better glycemic control. The significant effects of Survodutide on these parameters may lead to improved treatment strategies, potentially reducing the risk of diabetes-related complications and enhancing patients' quality of life.
Keep in mind
Limited generalizability due to specific participant characteristics. Potential unmeasured confounders affecting outcomes. Short duration of follow-up may not capture long-term effects.
Published in
Journal Reference
Publication details and source links for this paper.
Elif IE, Sandra GM, Anna U, Jorge AM, Anita MH, Corinna S. Survodutide Improves Beta-Cell Function and Insulin Sensitivity in Adults with Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2026;28(9):8242-8253. doi:10.1111/dom.70861
Main Effects
Survodutide significantly increased HOMA-β by 47 index points (p=0.0001).
Survodutide significantly decreased HOMA-IR by -0.91 index (p=0.0086).
Survodutide significantly reduced glucagon levels by -15.07 pmol/L (p=0.0001).
Survodutide significantly lowered fasting plasma glucose by -2.32 mmol/L (p=0.0001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Semaglutide, Survodutide and 1/HOMA-IR, Fasting Plasma Glucose (FPG), Glucagon, and 5 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
- 1/HOMA-IR
- Fasting Plasma Glucose (FPG)
- Glucagon
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
11
Evidence pairs
11
Relationships
6
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
6
Related topics
11
Evidence pairs
1449
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 11 evidence relationships
- Includes primary outcome data
- Linked to 6 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and Fasting Glucose
Related evidence
Evidence relationship
GLP-1 Receptor Agonists and Beta-cell Function
Save evidence
Evidence topic
Insulin Resistance
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Fasting Plasma Glucose (FPG)
Semaglutide → Fasting Plasma Glucose (FPG)
Semaglutide → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ImpactScore™
- 63
- Slightly Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 4 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerHomeostatic Model Assessment of Beta-cell function (HOMA-β)
Semaglutide → Homeostatic Model Assessment of Beta-cell function (HOMA-β)
Semaglutide → Homeostatic Model Assessment of Beta-cell function (HOMA-β)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerFasting Plasma Glucose (FPG)
Survodutide → Fasting Plasma Glucose (FPG)
Survodutide → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerHomeostatic Model Assessment of Beta-cell function (HOMA-β)
Survodutide → Homeostatic Model Assessment of Beta-cell function (HOMA-β)
Survodutide → Homeostatic Model Assessment of Beta-cell function (HOMA-β)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Survodutide improved beta-cell function significantly compared to placebo.
- Insulin resistance decreased notably with Survodutide treatment.
- Fasting plasma glucose levels were significantly reduced by Survodutide.
Who this applies to
- Adults diagnosed with Type 2 Diabetes.
- Participants who are not currently on insulin therapy.
Keep in Mind
- Results may not apply to populations outside the study's demographic.
- The study duration was limited, necessitating further long-term research.
- The effects of Survodutide compared to other diabetes treatments were not fully explored.
Between the Lines
- Limited generalizability due to specific participant characteristics.
- Potential unmeasured confounders affecting outcomes.
- Short duration of follow-up may not capture long-term effects.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Fasting Glucose, GLP-1 Receptor Agonists and Glucagon.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → Fasting Glucose
Medications
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ImpactScore™
- 63
- Slightly Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 4 studies
View evidenceMedications
GLP-1 Receptor Agonists → Glucagon
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Fasting Glucose Evidence Hub
All studies measuring Fasting Glucose
4 studies
outcome_hubMeasures Fasting Glucose as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
4 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Glucagon Evidence Hub
All studies measuring Glucagon
2 studies
outcome_hubMeasures Glucagon as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Semaglutide and Fasting Plasma Glucose (FPG)
Intervention: SemaglutideOutcome: Fasting Plasma Glucose (FPG)
4 results
All studies on Semaglutide and Glucagon
Intervention: SemaglutideOutcome: Glucagon
2 results
All studies on Semaglutide
Intervention: Semaglutide
4 results
All studies measuring Fasting Plasma Glucose (FPG)
Outcome: Fasting Plasma Glucose (FPG)
4 results
All studies measuring Glucagon
Outcome: Glucagon
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do GLP-1 Receptor Agonists improve fasting glucose?
Strong Evidence
GLP-1 Receptor Agonists may improve fasting glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 18 supporting studies with generally consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists improve beta-cell function?
Moderate Evidence
Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for beta-cell function.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Homeostatic Model Assessment of Beta-cell function (HOMA-β)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
Does Semaglutide improve glucagon?
Moderate Evidence
Current evidence does not show a clear benefit of Semaglutide for glucagon.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Glucagon
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Survodutide improve fasting plasma glucose (FPG)?
Emerging Evidence
Survodutide appears to improve fasting plasma glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesSemaglutide improves insulin sensitivity in adolescents with obesitySurvodutide may improve weight reduction in obesity with type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.